Treatment of H. pylori not linked with future C. difficile infection

Neither treatment of nor complete eradication of Helicobacter pylori infection was associated with future Clostridioides difficile infection in a large study of United States veterans, according to research published in The American Journal of Gastroenterology.Shria Kumar, MD, of the division of gastroenterology and hepatology at the Perelman School of Medicine at the University of Pennsylvania,…

Atezolizumab plus cobimetinib improves PFS in biliary tract cancer

Atezolizumab plus cobimetinib significantly prolonged PFS compared with atezolizumab alone among a cohort of patients with advanced biliary tract cancer, according to results of a phase 2 study presented at the virtual American Association for Cancer Research Annual Meeting.The combination also demonstrated manageable toxicity in what researchers described as the first randomized trial of immunotherapy…

Low risk for de-novo IBD in patients treated with bariatric surgery, weight loss medications

Patients who are obese and underwent treatment with either bariatric surgery or weight-loss medications compared with persistently obese patients not exposed to either intervention are at lower risk for development of de-novo inflammatory bowel disease, according to study results.“Future research is needed to understand the mechanism behind persistent or refractory obesity and development of inflammatory…

‘We’re in This Together’: COVID-19 and Gastroenterology

The COVID-19 pandemic has been an unprecedented crisis unlike anything seen in many decades. While infectious disease specialists have been on the front lines since the first outbreak of the disease, as more information comes out, the world is beginning to understand the role the gastrointestinal tract plays in the disease.According to the CDC, there…

FDA approves additional recommended dosage for Keytruda

The FDA approved an additional recommended dosage of pembrolizumab, authorizing its use at 400 mg every 6 weeks.The new dosage option — available in addition to the previously approved dose of 200 mg every 3 weeks — applies to all adult indications for pembrolizumab (Keytruda, Merck).The anti-PD-1 therapy is approved for use as monotherapy and…